Short-term pravastatin mediates growth inhibition and apoptosis, independently of Ras, via the signaling proteins p27(Kip1) and PI3 kinase

Journal of the American Society of Nephrology

Volumn 10, Issue 9, 1999, Pages 1880-1890

  Weiss, Robert H ^a,b,c   Ramirez, Al ^a   Joo, Adriane ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; DNA; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR BB; PRAVASTATIN; PROTEIN P27; RAF PROTEIN; RAS PROTEIN; RHO FACTOR;

ADENOSINE DIPHOSPHATE RIBOSYLATION; ANIMAL CELL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DILATATION; DNA SYNTHESIS; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GROWTH INHIBITION; HEMODIALYSIS; MITOGENESIS; NONHUMAN; PRIORITY JOURNAL; RAT; RESTENOSIS; VASCULAR ACCESS; VASCULAR DISEASE; VASCULAR SMOOTH MUSCLE;

EID: 0032803586     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/asn.v1091880     Document Type: Article

References (57)

1. Casey PJ: Protein lipidation in cell signaling. Science 268: 221-226, 1995
2. Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, Chia D, Terasaki PI, Sabad A, Cogert GA: Effect of pravastatin on outcomes after cardiac transplantation [see Comments]. N Engl J Med 333: 621-627, 1995
3. Weintraub WS, Boccuzzi SJ, Klein JL, Kosinski AS, King SB, Ivanhoe R, Cedarholm JC, Stillabower ME, Talley JD, DeMaio SJ: Lack of effect of lovastatin on restenosis after coronary angioplasty. Lovastatin Restenosis Trial Study Group. N Engl J Med 331: 1331-1337, 1994
4. Weiss RH, Maga EA, Ramirez A: MEK inhibition augments Raf activity, but has variable effects on mitogenesis, in vascular smooth muscle cells. Am J Physiol 274: C1521-C1529, 1998
5. Weiss RH, Nuccitelli R: Inhibition of tyrosine phosphorylation prevents thrombin-induced mitogenesis, but not intracellular free calcium release, in vascular smooth muscle cells. J Biol Chem 267: 5608-5613, 1992
6. Satoh T, Fantl WJ, Escobedo JA, Williams LT, Kaziro Y: Platelet-derived growth factor receptor mediates activation of ras through different signaling pathways in different cell types. Mol Cell Biol 13: 3706-3713, 1993
7. Weiss RH, Yabes AP: The mitogenic inhibitory effect of phorbol esters is associated with decreased activation of phosphatidylinositol-3 kinase. Am J Physiol 270: C619-C627, 1996
8. Hancock JF, Magee AI, Childs JE, Marshall CJ: All ras proteins are polyisoprenylated but only some are palmitoylated. Cell 57: 1167-1177, 1989
9. Silvius JR, l'Heureux F: Fluorimetric evaluation of the affinities of isoprenylated peptides for lipid bilayers. Biochemistry 33: 3014-3022, 1994
10. Ulsh LS, Shih TY: Metabolic turnover of human c-rasH p21 protein of EJ bladder carcinoma and its normal cellular and viral homologs. Mol Cell Biol 4: 1647-1652, 1984
11. Iwama A, Sawamura M, Nara Y, Yamori Y: Effect of lovastatin and fluoromevalonate on phosphatidylinositol 3-kinase activity stimulated with PDGF. Clin Exp Pharmacol Physiol 22[Suppl 1]: S318-S320, 1995
12. Munro E, Patel M, Chan P, Betteridge L, Clunn G, Gallagher K, Hughes A, Schachter M, Wolfe J, Sever P: Inhibition of human vascular smooth muscle cell proliferation by lovastatin: The role of isoprenoid intermediates of cholesterol synthesis. Eur J Clin Invest 24: 766-772, 1994
13. Corsini A, Mazzotti M, Raiteri M, Soma MR, Gabbiani G, Fumagalli R, Paoletti R: Relationship between mevalonate pathway and arterial myocyte proliferation: In vitro studies with inhibitors of HMG-CoA reductase. Atherosclerosis 101: 117-125, 1993
14. Ullrich A, Schlessinger J: Signal transduction by receptors with tyrosine kinase activity. Cell 61: 203-212, 1990
15. McGuire TF, Qian Y, Vogt A, Hamilton AD, Sebti SM: Platelet-derived growth factor receptor tyrosine phosphorylation requires protein geranylgeranylation but not farnesylation. J Biol Chem 271: 27402-27407, 1996
16. Stokoe D, MacDonald SG, Cadwallader K, Symons M, Hancock JF: Activation of raf as a result of recruitment to the plasma membrane. Science 264: 1463-1467, 1994
17. Furth ME, Aldrich TH, Cordon-Cardo C: Expression of ras proto-oncogene proteins in normal human tissues. Oncogene 1: 47-58, 1987
18. Fantl WJ, Escobedo JA, Martin GA, Turck CW, Del Rosario M, McCormick F, Williams LT: Distinct phosphotyrosines on a growth factor receptor bind to specific molecules that mediate different signaling pathways. Cell 69: 413-423, 1992
19. Valius M, Kazlauskas A: Phospholipase C-gamma-1 and phosphatidylinositol 3 kinase are the downstream mediators of the PDGF receptor's mitogenic signal. Cell 73: 321-334, 1993
20. Joly M, Kazlauskas A, Fay FS, Corvera S: Disruption of PDGF receptor trafficking by mutation of its PI-3 kinase binding sites. Science 263: 684-687, 1994
21. Valgeirsdottir S, Eriksson A, Nister M, Heldin CH, Westermark B, Claesson-Welsh L: Compartmentalization of autocrine signal transduction pathways in Sis-transformed NIH 3T3 cells. J Biol Chem 270: 10161-10170, 1995
22. Khwaja A, Rodriguez-Viciana P, Wennstrom S, Warne PH, Downward J: Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway. EMBO J 16: 2783-2793, 1997
23. Pap M, Cooper GM: Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-Kinase/Akt cell survival pathway. J Biol Chem 273: 19929-19932, 1998
24. Karnitz LM, Burns LA, Sutor SL, Blenis J, Abraham RT: Interleukin-2 triggers a novel phosphatidylinositol 3-kinase-dependent MEK activation pathway. Mol Cell Biol 15: 3049-3057, 1995
25. mapk are required for fibroblast proliferation. Proc Natl Acad Sci USA 90: 8319-8323, 1993
26. Janknecht R, Ernst WH, Pingoud V, Nordheim A: Activation of ternary complex factor Elk-1 by MAP kinases. EMBO J 12: 5097-5104, 1993
27. Yang SH, Yates PR, Whitmarsh AJ, Davis RJ, Sharrocks AD: The Elk-1 ETS-domain transcription factor contains a mitogen-activated protein kinase targeting motif. Mol Cell Biol 18: 710-720, 1998
28. Whitmarsh AJ, Shore P, Sharrocks AD, Davis RJ: Integration of MAP kinase signal transduction pathways at the serum response element. Science 269: 403-407, 1995
29. Woods D, Parry D, Cherwinski H, Bosch E, Lees E, McMahon M: Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1. Mol Cell Biol 17: 5598-5611, 1997
30. Evan G, Littlewood T: A matter of life and cell death. Science 281: 1317-1322, 1998
31. Ravi RK, Weber E, McMahon M, Williams JR, Baylin S, Mal A, Harter ML, Dillehay LE, Claudio PP, Giordano A, Nelkin BD, Mabry M: Activated Raf-1 causes growth arrest in human small cell lung cancer cells. J Clin Invest 101: 153-159, 1998
32. Ferrier AF, Lee M, Anderson WB, Benvenuto G, Morrison DK, Lowy DR, DeClue JE: Sequential modification of serines 621 and 624 in the Raf-1 carboxyl terminus produces alterations in its electrophoretic mobility. J Biol Chem 272: 2136-2142, 1997
33. Wartmann M, Hofer P, Turowski P, Saltiel AR, Hynes NE: Negative modulation of membrane localization of the Raf-1 protein kinase by hyperphosphorylation. J Biol Chem 272: 3915-3923, 1997
34. Sewing A, Wiseman B, Lloyd AC, Land H: High-intensity Raf signal causes cell cycle arrest mediated by p21Cip1. Mol Cell Biol 17: 5588-5597, 1997
35. Kumagai N, Morii N, Fujisawa K, Nemoto Y, Narumiya S: ADP-ribosylation of rho p21 inhibits lysophosphatidic acid-induced protein tyrosine phosphorylation and phosphatidylinositol 3-kinase activation in cultured Swiss 3T3 cells. J Biol Chem 268: 24535-24538, 1993
36. Zhang J, King WG, Dillon S, Hall A, Feig L, Rittenhouse SE: Activation of platelet phosphatidylinositide 3-kinase requires the small GTP-binding protein Rho. J Biol Chem 268: 22251-22254, 1993
37. Waf1/Cip1. Nature 394: 295-299, 1998
38. Weber JD, Hu W, Jefcoat SCJ, Raben DM, Baldassare JJ: Ras-stimulated extracellular signal-related kinase 1 and RhoA activities coordinate platelet-derived growth factor-induced G1 progression through the independent regulation of cyclin D1 and p27. J Biol Chem 272: 32966-32971, 1997
39. Lebowitz PF, Davide JP, Prendergast GC: Evidence that farnesyltransferase inhibitors suppress Ras transformation by interfering with Rho activity. Mol Cell Biol 15: 6613-6622, 1995
40. Bourmeyster N, Boquet P, Vignais PV: Role of bound GDP in the stability of the rho A-rho GDI complex purified from neutrophil cytosol. Biochem Biophys Res Commun 205: 174-179, 1994
41. Kip1. J Am Soc Nephrol 9: 2235-2243, 1999
42. Ridley AJ, Hall A: The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell 70: 389-399, 1992
43. Malcolm KC, Elliott CM, Exton JH: Evidence for Rho-mediated agonist stimulation of phospholipase D in rat1 fibroblasts: Effects of Clostridium botulinum C3 exoenzyme. J Biol Chem 271: 13135-13139, 1996
44. Lloyd AC, Obermuller F, Staddon S, Barth CF, McMahon M, Land H: Cooperating oncogenes converge to regulate cyclin/cdk complexes. Genes Dev 11: 663-677, 1997
45. Hirai A, Nakamura S, Noguchi Y, Yasuda T, Kitagawa M, Tatsuno I, Oeda T, Tahara K, Terano T, Narumiya S, Kohn LD, Saito Y: Geranylgeranylated rho small GTPase(s) are essential for the degradation of p27Kip1 and facilitate the progression from G1 to S phase in growth-stimulated rat FRTL-5 cells. J Biol Chem 272: 13-16, 1997
46. McGuire TF, Xu XQ, Corey SJ, Romero GG, Sebti SM: Lovastatin disrupts early events in insulin signaling: A potential mechanism of lovastatin's anti-mitogenic activity. Biochem Biophys Res Commun 204: 399-406, 1994
47. Rameh LE, Chen CS, Cantley LC: Phosphatidylinositol (3,4,5)P3 interacts with SH2 domains and modulates PI 3-kinase association with tyrosine-phosphorylated proteins. Cell 83: 821-830, 1995
48. DeClue JE, Vass WC, Papageorge AG, Lowy DR, Willumsen BM: Inhibition of cell growth by lovastatin is independent of ras function. Cancer Res 51: 712-717, 1991
49. Noguchi Y, Nakamura S, Yasuda T, Kitagawa M, Kohn LD, Saito Y, Hirai A: Newly synthesized Rho A, not Ras, is isoprenylated and translocated to membranes coincident with progression of the G1 to S phase of growth-stimulated rat FRTL-5 cells. J Biol Chem 273: 3649-3653, 1998
50. Guijarro C, Blanco-Colio LM, Ortego M, Alonso C, Ortiz A, Plaza JJ, Diaz C, Hernandez G, Edigo J: 3-Hydroxy-3-methyl-glutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ Res 83: 490-500, 1998
51. Hengst L, Reed SI: Translational control of p27Kip1 accumulation during the cell cycle. Science 271: 1861-1864, 1996
52. Baetta R, Donetti E, Comparato C, Calore M, Rossi A, Teruzzi C, Paoletti R, Fumagalli R, Soma MR: Proapoptotic effect of atorvastatin on stimulated rabbit smooth muscle cells. Pharmacol Res 36: 115-121, 1997
53. Lebowitz PF, Sakamuro D, Prendergast GC: Farnesyl transferase inhibitors induce apoptosis of Ras-transformed cells denied sub-stratum attachment. Cancer Res 57: 708-713, 1997
54. Thibault A, Samid D, Tompkins AC, Figg WD, Cooper MR, Hohl RJ, Trepel J, Liang B, Patronas N, Venzon DJ, Reed E, Myers CE: Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res 2: 483-491, 1996
55. Cox AD, Der CJ: Farnesyltransferase inhibitors and cancer treatment: Targeting simply Ras? Biochim Biophys Acta 1333: F51-F71, 1997
56. Khosravi-Far R, Cox AD, Kato K, Der CJ: Protein prenylation: Key to ras function and cancer intervention? Cell Growth Differ 3: 461-469, 1992
57. Pan HY, DeVault AR, Wang-Iverson D, Ivashkiv E, Swanson BN, Sugerman AA: Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin. J Clin Pharmacol 30: 1128-1135, 1990